Silexion Therapeutics Executes 1-for-10 Reverse Share Split to Meet Nasdaq Listing Standards
Event summary
- Silexion Therapeutics will implement a 1-for-10 reverse share split effective May 28, 2026, with adjusted trading beginning May 29, 2026.
- The split consolidates every 10 shares into 1, increasing the par value from $0.0135 to $0.135 per share.
- The move aims to comply with Nasdaq’s minimum bid price requirement and reduce share volatility.
- Silexion plans to initiate a Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer this quarter.
- CEO Ilan Hadar cites the split as a step to strengthen capital structure ahead of clinical milestones.
The big picture
Silexion’s reverse share split is a defensive maneuver to maintain Nasdaq listing amid low stock price pressures, a common strategy for clinical-stage biotechs facing liquidity constraints. The move aligns with broader industry trends where companies prioritize shareholder value and market stability ahead of pivotal clinical trials. Success hinges on whether the split translates into sustained investor confidence and funding agility.
What we're watching
- Clinical Execution
- How the Phase 2/3 trial of SIL204 progresses and whether it meets regulatory benchmarks.
- Market Positioning
- Whether the reverse split attracts new investors and stabilizes the share price.
- Funding Flexibility
- The pace at which Silexion secures additional capital to advance SIL204.
Related topics